MoonLake Immunotherapeutics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, MoonLake Immunotherapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 2 completed later-stage tilt upper quartile by trial count

MoonLake Immunotherapeutics: 7 sponsored US clinical trials, 2 recruiting.

MoonLake Immunotherapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 5 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arthritis, Psoriatic, with 3 trials.

Upper-quartile sponsor footprint

MoonLake Immunotherapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

NCT06768671
RECRUITING Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
ACTIVE NOT RECRUITING Phase 3

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411899
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06411379
COMPLETED Phase 2

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

NCT05640245
COMPLETED Phase 2

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 5

Therapeutic Areas

Arthritis, Psoriatic 3
Hidradenitis Suppurativa 3

Where MoonLake Immunotherapeutics enrollment is open (later-stage tilt)

2 recruiting of 7 indexed (29% open); 2 completed (29%).

Phase mix: 5 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Arthritis, Psoriatic (3 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

MoonLake Immunotherapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share MoonLake Immunotherapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

MoonLake Immunotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this MoonLake Immunotherapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of MoonLake Immunotherapeutics or any single study.

  • 2 of MoonLake Immunotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Arthritis, Psoriatic is the condition MoonLake Immunotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arthritis, Psoriatic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

MoonLake Immunotherapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.